The A variant was found to decrease VEGF binding efficiency [47] and soluble VEGFR2 levels in coronary artery disease [58], whereas, in another study, an increased MVD and protein phosphorylation in NSCLC tumors were associated with A allele [46]. This evidence concerns the gene VEGFA and coronary artery disorder.